Horizons of development of immunotherapy for malignant liver tumors

Author:

Mukhin V. E.1ORCID,Konstantinova Yu. S.1ORCID,Gimadiev R. R.2ORCID,Mazurchik N. V.2ORCID

Affiliation:

1. Federal State Budgetary Institution “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Federal Medical Biological Agency

2. Federal State Autonomous Educational Institution for Higher Education “Peoples’ Friendship University of Russia”

Abstract

Primary liver tumors are one of the most common types of malignant neoplasms. Surgical excision is still the most effective treatment in the early stages of the disease, however in most cases early diagnosis is difficult. Moreover, even if the treatment is carried out according to a radical program, the risk of relapse remains extremely high. In this regard, the search for new strategies for the treatment of liver malignancies that differ from traditional methods of treatment is not terminated. One of such promising approaches is immunotherapy. The present review is devoted to the current understanding of the mechanisms of action and the available clinical experience in the use of immunotherapy approaches in the treatment of liver malignancies. Combining different types of immunotherapy or combining immunotherapy with traditional therapeutic approaches can facilitate a synergistic effect and contribute to the development of personalized medicine.

Publisher

LLC Global Media Technology

Subject

General Medicine

Reference48 articles.

1. Chekmazov IA, Ivanikov IO, Sapronov GV, Kirillova NCh, Vinogradova NN. Liver cancer: etiology, pathogenesis, results of long-term clinical and epidemiological observation (in Russian only). Russian journal of Evidence-based gastroenterology = Dokazatel’naya gastroenterologiya. 2019;8(1):5-15. (In Russ.) Doi: 10.17116/dokgastro201980115@@ Chekmazov I. A., Ivanikov I. O., Sapronov G. V., Kirillova N. Ch., Vinogradova N. N. Rak pecheni: etiologiya, patogenez, itogi dlitel'nogo kliniko-epidemiologicheskogo nablyudeniya. Dokazatel'naya gastroenterologiya. 2019;8(1):5-15.

2. Shchegolev AI, Tumanova UN, Mishnev OD. Risk factors of hepatocellular carcinoma. International journal of applied and fundamental research. 2018; 9:164-169. (In Russ.)@@ Shchegolev A. I., Tumanova U. N., Mishnev O. D. Faktory riska razvitiya gepatotsellyulyarnoi kartsinomy. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii. 2018;9:164-169.

3. Ozakyol A. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). J Gastrointest Canc. 2017; 48:238-240. Doi: 10.1007/s12029-017-9959-0.

4. Merabishvili V.M., Chepik O.f., Merabishvili E. N. Dynamics of observed and relative survival of patients with primary liver cancer on the population level according to disease stage and histological structure. Siberian journal of oncology. 2015;1(4):5-11. (In Russ.)@@ Merabishvili V. M., Chepik O. F., & Merabishvili E. N. Dinamika nablyudaemoi i otnositel'noi vyzhivaemosti bol'nykh pervichnym rakom pecheni na populyatsionnom urovne s uchetom stadii zabolevaniya i gistologicheskoi struktury. Sibirskii onkologicheskii zhurnal. 2015; (4), 5-11.

5. Moini M., Schilsky M. L., Tichy E. M. Review on immunosuppression in liver transplantation. World journal of hepatology. 2015; 7(10):1355. Doi: 10.4254/wjh.v7.i10.1355

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3